Electronic Resource
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial
| العنوان: | Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial |
|---|---|
| المؤلفون: | Tom, J, Bao, M, Tsai, L, Qamra, A, Summers, D, Carrasco-Triguero, M, Mcbride, J, Rosenberger, C, Lin, C, Stubbings, W, Blyth, K, Carratalà, J, François, B, Benfield, T, Haslem, D, Bonfanti, P, van der Leest, C, Rohatgi, N, Wiese, L, Luyt, C, Kheradmand, F, Rosas, I, Cai, F, Tom, Jennifer, Bao, Min, Tsai, Larry, Qamra, Aditi, Summers, David, Carrasco-Triguero, Montserrat, McBride, Jacqueline, Rosenberger, Carrie M., Lin, Celia J. F., Stubbings, William, Blyth, Kevin G., Carratalà, Jordi, François, Bruno, Benfield, Thomas, Haslem, Derrick, Bonfanti, Paolo, van der Leest, Cor H., Rohatgi, Nidhi, Wiese, Lothar, Luyt, Charles Edouard, Kheradmand, Farrah, Rosas, Ivan O., Cai, Fang |
| بيانات النشر: | Lippincott Williams & Wilkins country:US 2022 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | OBJECTIVES: To explore candidate prognostic and predictive biomarkers identified in retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, ferritin, lymphocytes, monocytes, neutrophils, d-dimer, and platelets) in patients with coronavirus disease 2019 pneumonia after treatment with tocilizumab, an anti-interleukin-6 receptor antibody, using data from the COVACTA trial in patients hospitalized with severe coronavirus disease 2019 pneumonia. DESIGN: Exploratory analysis from a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. SETTING: Hospitals in North America and Europe. PATIENTS: Adults hospitalized with severe coronavirus disease 2019 pneumonia receiving standard care. INTERVENTION: Randomly assigned 2:1 to IV tocilizumab 8 mg/kg or placebo. MEASUREMENTS AND MAIN RESULTS: Candidate biomarkers were measured in 295 patients in the tocilizumab arm and 142 patients in the placebo arm. Efficacy outcomes assessed were clinical status on a seven-category ordinal scale (1, discharge; 7, death), mortality, time to hospital discharge, and mechanical ventilation (if not receiving it at randomization) through day 28. Prognostic and predictive biomarkers were evaluated continuously with proportional odds, binomial or Fine-Gray models, and additional sensitivity analyses. Modeling in the placebo arm showed all candidate biomarkers except lactate dehydrogenase and d-dimer were strongly prognostic for day 28 clinical outcomes of mortality, mechanical ventilation, clinical status, and time to hospital discharge. Modeling in the tocilizumab arm showed a predictive value of ferritin for day 28 clinical outcomes of mortality (predictive interaction, p = 0.03), mechanical ventilation (predictive interaction, p = 0.01), and clinical status (predictive interaction, p = 0.02) compared with placebo. CONCLUSIONS: Multiple biomarkers prognostic for clinical outcomes were confirmed in COVACTA. Ferritin was identified as a predic |
| مصطلحات الفهرس: | biomarker, coronavirus disease 2019, ferritin, interleukin-6, severe acute respiratory syndrome coronavirus 2, tocilizumab, info:eu-repo/semantics/article |
| URL: | info:eu-repo/semantics/altIdentifier/pmid/34612846 info:eu-repo/semantics/altIdentifier/wos/WOS:000759057200032 volume:50 issue:3 (1 March 2022) firstpage:398 lastpage:409 numberofpages:12 journal:CRITICAL CARE MEDICINE |
| الاتاحة: | Open access content. Open access content |
| ملاحظة: | STAMPA English |
| Other Numbers: | ITBAO oai:boa.unimib.it:10281/330058 10.1097/CCM.0000000000005229 info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85125006461 1308941104 |
| المصدر المساهم: | BICOCCA OPEN ARCH From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1308941104 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |